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Stroke is a global cause of morbidity and mortality, ranking fourth
among all causes of death.1 Although considerable progress has
been made in developing effective tools for acute stroke treatment,
at present the only drug approved is recombinant tissue plasminogen
activator (rt-PA); thus, new strategies for its effective prevention and
treatment are essential. Following ischaemia/reperfusion, the
blood–brain barrier (BBB) becomes more permeable and, in doing
so, it promotes an increased infiltration of pro-inflammatory cells,
resulting in the so-called ‘reperfusion injury’.2Given its key role inme-
diating ischaemia/reperfusion-related neuronal damage, the BBB is a
central target for the development of novel therapeutical strategies.
Bouleti and colleagues have provided an elegant study reporting a
new target improving stroke outcome in mice.3 Their study shows
that angiopoietin-like 4 (ANGPTL4) modulates endothelial perme-
ability following ischaemia/reperfusion and thus represents a poten-
tial new therapeutical target for the treatment of stroke.
ANGPTL4, first discovered in 2000, was originally classified as an
adipokine playing roles in lipid metabolism.4 Over the last decade,
ANGPTL4has been recognized toplayadditional roles in tumorigen-
esis, angiogenesis, and redox regulation.4 Bouleti and colleagues
investigated the role of ANGPTL4 in stroke by using a transient
focal cerebral ischaemia murine model, where the middle cerebral
artery was occluded for 1 h, followed by 24 h of reperfusion.
Indeed, they could show that recombinant human ANGPTL4
(rhANGPTL4) treatment prior to the ischaemic episode greatly
reduced the stroke size and consequent neurological deficit. To
provide additional supporting evidence for the protective effects of
ANGPTL4, Bouleti et al. analysed stroke outcome in ANGPTL4
knockout mice undergoing ischaemic stroke. Moreover, to translate
their findings into a more clinically relevant experimental set-up, the
authors treated mice with rhANGPTL4 upon reperfusion, 1 h after
the ischaemic event. Both in ANGPTL4 knockout mice and in the
post-ischaemic rhANGPTL4-treated mice, the authors could
confirm the protective effects of ANGPTL4 on stroke. Finally, to
test the responsiveness of ANGPTL4 to stroke also in humans,
Bouleti et al. stained brain samples of patients who had previously
died from ischaemic stroke and demonstrated an increased expres-
sion of ANGPTL4.
Given the key role of vascular integrity in determining stroke
outcome,2Bouleti andcolleagues focusedonanalysingendothelial net-
works to characterize theprotective effects of rhANGPTL4 treatment
on stroke outcome. They demonstrated an improved endothelial
network after ischaemia/reperfusion brain injury in the rhANGPTL4-
treated mice as compared with controls, indicating a preservation of
the vasculature during stroke. Cerebral endothelial cells build the
initial barrier of the BBB separating blood components from brain
cells, andareconnectedby tight andadherens junctionproteins.5Adis-
ruption of these cell–cell contacts leads to vascular leakage, oedema
formation, and brain damage. In the present work, the integrity of
tight and adherens junctions was assessed by characterizing claudin-5
and VE-cadherin, two main junction proteins.5 The authors showed
an increase in claudin-5- and VE-cadherin-positive areas after ischae-
mia/reperfusion injury in the rhANGPTL4-treated mice compared
with the control mice, indicating an effect of ANGPTL4 on preserving
the integrity of tight and adherens junctions in stroke.
Acutely, vascular endothelial growth factor (VEGF) is a potentme-
diatorof vascular permeability, and its antagonismhas been shown to
reduce ischaemia/reperfusion-related brain oedema and injury.6
Given the important role of VEGF as a mediator of acute vascular
leakage following ischaemia7 (Figure 1), Bouleti et al. tested the possi-
bility that rhANGPTL4 treatmentmay act by disrupting VEGF recep-
tor 2 (VEGFR2) signalling. Indeed, they showed that ANGPTL4
maintains vascular integrity via inhibition of VEGF-induced, VEGFR2-
mediated, disruption of VE-cadherin and claudin-5; a process in turn
depending on Src phosphorylation and phosphoinositid-3 kinase
(PI3K)/Akt activation (Figure 1).
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Transmigration of circulating cells from the vasculature into the
brain is a key step in tissue damage following ischaemia/reperfusion
injury. This event is promoted, in part, by an up-regulation of endo-
thelial adhesion molecules. Bouleti and colleagues demonstrated
that rhANGPTL4 treatment reduces intercellular adhesion
molecule-1 (ICAM-1) expression in the ipsilateral hemisphere of
rhANGPTL4-treated mice as compared with controls, indicating
that ANGPTL4 may also interfere with inflammatory responses fol-
lowing ischaemia/reperfusion.
In the clinical setting, rt-PA was first approved by the Food and
Drug Administration (FDA) in 2006 for the treatment of ischaemic
stroke within 3 h from symptom onset, after the publication of the
NINDS trial,8 in which a 12% absolute (32% relative) increase in
the number of patients with minimal or no disability was achieved
in the rt-PA group compared with placebo. However, access to
rt-PA is limited by numerous contraindications, which make this
treatment available only for a minority of patients. In addition,
rt-PA treatment is burdened by a major complication, i.e. haemor-
rhagic evolution of the ischaemic lesion, which is one of the principal
reasons given by many emergency room physicians and neurologists
for their avoidance of use of rt-PA therapy.
In their study, Bouleti et al. demonstrate that administration of
ANGPTL4 in an ischaemic stroke model decreases infarct size and
improves neurological function by maintaining vascular integrity
through prevention of BBB breakdown.
From a clinical perspective, these data are very interesting, as we
do know that BBB breakdown is involved in both ischaemic and haem-
orrhagic stroke, as well as in the haemorrhagic transformation of is-
chaemic stroke, either spontaneously or after rt-PA administration.
However, even if numerous neuroprotective agents have already
been shown to be effective in ameliorating outcome in experimental
models of stroke, to date clinical neurologists are facedwith a long list
of failures in the translation into the clinical setting. To address this
issue, the Stroke Therapy Academic Industry Roundtable (STAIR)
published in 1999 recommendations to improve the quality of pre-
clinical studies of acute stroke therapies,9 further updated in
2009.10 These guidelines include, first of all, methodological stan-
dards, such as random allocation, allocation concealment, sample
size calculation, inclusion and exclusion criteria, randomization,
reporting of animals excluded from analysis, and blinded assessment
of outcome, as well as reporting of potential conflicts of interest and
study funding. In addition, the authors underline the intrinsic limita-
tions of animal strokemodels, themost relevant being that ischaemia
is experimentally induced in otherwise healthy animals, whereas
human stroke occurs in the context of different risks factors and con-
comitantmedications. Finally, accumulating data suggest thatmanyof
the neuroprotective targets tested in preclinical models may have a
negative effect on the recovery process. Thus, any acute therapy
must consider whether the desired target plays a role in the subse-
quent process of recovery. Accordingly, multiple endpoints, such
as histological endpoints, biologicalmarkers, imaging data, andbehav-
ioural and functional outcomes, should be carefully identified and
tested at the appropriate time points. In line with these considera-
tions, many of the animal models demonstrated optimal benefit in a
time frame that was not practical for clinical stroke intervention,
such as either pre-treatment or within 90 min of the infarction.
Because the onset-to-needle time in the real world is relatively long,
the timewindow in animal experiments shouldbe defined accordingly.
Bouleti and colleagues showvery convincingly and indetail the vas-
culoprotective properties of ANGPTL4 in ischaemic stroke. In par-
ticular, the post-ischaemic treatment with rhANGPTL4 provides
clinical relevance and sets the basis for follow-up investigations.
However, there are also some limitations to this work, which
should be mentioned. First of all, all analyses concerning stroke
size, neurological deficit, and mechanisms are performed at short
time points and no data are provided to confirm the protective
effects of rhANGPTL4 treatment beyond 24 h. Given the known bi-
phasic nature of some of the molecular signals activated during
stroke, the role of ANGPTL4 in vascular integrity and stroke
outcome should also be studied long term to elucidate fully its thera-
peutic potential. Secondly, most in vitro experiments are conducted
on human endothelial cells of venous or dermal origin while we
feel that mechanistic studies should also be confirmed on human
endothelial cells originating from cerebral arteries to exclude
possible cell type-specific effects.
Recently, stroke research reached beyond the role of the BBB;
indeed, a number of other approaches have also been considered.
Free radicals are important mediators of BBB damage following
ischaemia; thus, different strategies to prevent the surge of reactive
oxygen species have been successfully studied.11,12 Additionally,
much focus has also been put on studying the therapeutic potential
of stem cell transplantation in stroke patients. Although its effective-
ness in stroke animalmodels13 as well as its clinical safety and feasibil-
ity were demonstrated,14 the clinical efficacy of stem cell therapy still
has to be improved15 so as to become a concrete therapeutic alter-
native, and at present this scenario still seems far away.
Figure 1 Schematic representation of the molecular mechan-
isms activated in response to ischaemia and downstream of
VEGFR2 involving Src, PI3-Akt and ANGPTL4, ultimately leading
to disruption of VE-cadherin and claudin-5.
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Wedo hope that, if the results obtained by Bouleti and colleagues
are confirmed by further experiments adhering to the suggested
recommendations, any clinical trial implemented will not run into
previously observed trivialities. The world outside desperately
needs effective new therapies to combat stroke, which every year
causes millions of people to become disabled, and is likely to cause
even more with the ageing population.
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